Miflonide Breezhaler (Budesonide)

Budesonide, the active ingredient in Miflonide Breezhaler, is an inhaled corticosteroid presented as an inhalation powder for inhalation use. It reduces airway inflammation and hyper‑responsiveness in patients with asthma and chronic obstructive pulmonary disease. It is formulated for delivery via the Breezhaler device, providing consistent dose distribution and rapid onset of action.

GNH USA supplies Miflonide Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice, ensuring product integrity throughout the supply chain, and partners with procurement teams across Europe, Asia, Africa and the Americas.

Miflonide Breezhaler, an inhaled corticosteroid, acts on airway inflammation in respiratory disease.

Asthma: improves control of symptoms and reduces frequency of exacerbations. COPD: decreases airway inflammation and helps maintain lung function. Chronic bronchitis: reduces inflammation of the bronchial tubes and supports better airway clearance.

Adverse reactions may occur with inhaled budesonide therapy.

Common Side Effects: - Oral thrush (candidiasis) - Hoarseness or voice change - Cough after inhalation - Upper respiratory tract infection

Serious or Rare Side Effects: - Pneumonia, particularly in COPD patients - Adrenal suppression with high‑dose or prolonged use - Osteoporosis or decreased bone mineral density over long term - Glaucoma or cataract formation with chronic exposure

Use of Miflonide Breezhaler requires careful consideration of several safety aspects.

Assess infection risk: monitor for signs of respiratory infection before initiating therapy. Use mouth rinse: advise patients to rinse mouth after inhalation to reduce oral candidiasis. Avoid abrupt discontinuation: taper dose under medical supervision to prevent adrenal insufficiency. Monitor bone health: consider calcium/vitamin D supplementation for long‑term users. Pregnancy and lactation: evaluate benefit‑risk ratio with prescriber. Store at ambient temperature: keep in original container, protect from moisture and heat.

Budesonide may interact with other medicines, affecting its safety or effectiveness.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic budesonide exposure. - Concomitant use of systemic corticosteroids: risk of additive glucocorticoid effects.

Moderate Interactions (Monitor Closely): - Ritonavir: may modestly raise budesonide levels. - Diuretics: may enhance risk of hypokalemia when combined with high‑dose inhaled steroids. - Antifungal azoles (e.g., fluconazole): possible interaction, monitor clinical response.